Clinical Trials Logo

Immune Thrombocytopenia clinical trials

View clinical trials related to Immune Thrombocytopenia.

Filter by:

NCT ID: NCT00902018 Completed - Clinical trials for Immune Thrombocytopenia

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

Start date: January 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to further evaluate the effects that eltrombopag (and romiplostim) have on platelets in subjects with chronic ITP. Eltrombopag is approved by the Food and Drug Administration (FDA) for the treatment of low platelets in patients with chronic ITP. It is being further studied by GlaxoSmithKline (now Novartis) in other conditions associated with low platelets. This research study is being done because eltrombopag has been shown to increase platelet counts in a different way than other therapies for ITP. The investigators want to further study how eltrombopag and romiplostim affect subjects and their platelets to determine how the study drug should best be used in ITP treatment.